We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cancer Cells Manipulate Ribosomes for Immune Evasion

A ribosome.
Credit: Netherlands Cancer Institute.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Summary 

Researchers at The Netherlands Cancer Institute found that cancer cells can modify their ribosomes to enhance their ability to hide from the immune system. By increasing ribosomes with a flexible arm, cancer cells reduce surface protein exposure, making them less visible and potentially aiding their resistance to immunotherapies.

Key Takeaways

  • Cancer cells manipulate their ribosomes to evade the immune system's detection.
  • Ribosomes are more diverse and dynamic than previously understood, affecting immune response.
  • Understanding ribosome modifications may lead to new strategies to enhance cancer immunotherapy effectiveness.

  • The protein factories of our cells are much more diverse than we thought they were. Scientists from The Netherlands Cancer Institute have now shown that cancer cells can use these ribosomes to boost their invisibility cloak, helping them hide from the immune system. The team publishes their findings in Cell today.


    “These findings make us change how we think about ribosomes.”


    Our immune system is constantly monitoring our body. In order to survive, cancer cells need to evade this inspection. “Making cells more visible to the immune system has revolutionized treatment”, says researcher Liam Faller from the Netherlands Cancer Institute. “However, many patients don’t respond to these immunotherapies or become resistant.” How cancer cells manage to circumvent elimination by the immune system is still a million-dollar question, though.